DSpace logo

Use este identificador para citar ou linkar para este item: http://repositorioinstitucional.uea.edu.br//handle/riuea/4112
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorAffonso, Juliana dos Santos-
dc.date.available2022-08-10-
dc.date.available2022-08-11T16:46:58Z-
dc.date.issued2020-07-15-
dc.identifier.urihttp://repositorioinstitucional.uea.edu.br//handle/riuea/4112-
dc.description.abstractThe hepatitis Delta virus is one of the main factors responsible for fulminant hepatitis in cases of acute infection and causes the accelerated progression of liver disease in chronic HBV carriers. The SNPs located in the promoter regions of the TNFɑ -308G/A, IL6 -174G/C and IL10 -1082A/G genes may be related to fibrosis progression, liver cirrhosis, development of CHC and risk of death. Objective: To evaluate the influence of polymorphisms on the genes for Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6) and Interleukin 10 (IL-10) genes in patients with Delta Hepatitis. Study design: The study population consisted of seventy-seven (77) patients with hepatitis Delta and one hundred and thirty-seven (137) eligible blood donors who make up the control group. The genomic regions of interest of the IL6, TNFα and IL10 genes were amplified by PCR-RFLP. The measurement of cytokines was performed by flow cytometry. Results: The G/A genotypes (TNFα -308G/A) and G/C (IL6 -174G/C) appear to be risk factors for HDV infection. The analysis of serum cytokine concentrations in the HDV group showed that cytokines IL-2 (p<0.0001), IL-4 (p<0.0001), IL-6 (p<0.0001), IL-10 (p<0.0031) found significantly increased in the HDV group. Serum cytokine levels for individuals in the HDV group IL-6G/C+C/C + IL-10A/G+G/G demonstrated higher levels of cytokines IL-2 (p<0.0066), IL-4 (p<0.0053), IL-6 (p<0.0076), IL-10 (p<0.0309) and IFN-γ (p<0.0199). Conclusion: Our findings demonstrate relevance on the influence of the studied SNPs in patients with HDV on the cytokine profile. TNFɑ -308G/A and IL6 -174G/C may predispose individuals to Hepatitis D infection. The presence of the combined IL-6G / C + CC + IL-10A / G + G / G genotypes alters the profile of the cytokines IL-2, IL-4, IL-6, IL-10 and IFN-γ. However, future studies must be carried out to better elucidate the influence of these SNPs on the pathogenesis of Hepatitis Deltapt_BR
dc.languageporpt_BR
dc.publisherUniversidade do Estado do Amazonaspt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectVírus da Hepatite Deltapt_BR
dc.subjectFibrosept_BR
dc.subjectPolimorfismospt_BR
dc.subjectCitocinaspt_BR
dc.subjectDelta Hepatitis Viruspt_BR
dc.titleEstudo de caracterização dos polimorfismos das regiões promotoras das citocinas fator de necrose tumoral a (TNF-a), interleucina 6(IL-6) e interleucina 10(IL-10) em pacientes com hepatite Deltapt_BR
dc.title.alternativeStudy of the characterization of polymorphisms of the promoter regions of the cytokines tumor necrosis factor a (TNF-a), interleukin 6(IL-6) and interleukin 10(IL-10) in patients with hepatitis Deltapt_BR
dc.typeDissertaçãopt_BR
dc.date.accessioned2022-08-11T16:46:58Z-
dc.contributor.advisor-co1Victoria, Marilu Barbieri-
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/0379575219138679pt_BR
dc.contributor.advisor1Tarragô, Andréa Monteiro-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/4644326589690231pt_BR
dc.contributor.referee1Moura Neto, José Pereira de-
dc.contributor.referee1Latteshttp://lattes.cnpq.br/6749773067557179pt_BR
dc.contributor.referee2Esashiba, Myuki Alfaia-
dc.contributor.referee3Castilho, Marcia da Costa-
dc.contributor.referee3Latteshttp://lattes.cnpq.br/2945789466069728pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/2712153635393688pt_BR
dc.description.resumoO vírus da hepatite Delta é um dos principais fatores responsáveis pela hepatite fulminante nos casos de infecção aguda e causa a progressão acelerada da doença hepática em portadores crônicos do VHB. Os SNPs localizados nas regiões promotoras dos genes TNFɑ -308G/A, IL6 -174G/C e IL10 -1082A/G podem estar relacionados à progressão da fibrose, cirrose hepática, desenvolvimento de CHC e risco de morte. OBJETIVO: Avaliar a influência dos polimorfismos nos genes das interleucinas Fator de Necrose Tumoral α (TNF-α), da Interleucina 6 (IL-6) e da Interleucina 10 (IL-10) em pacientes com Hepatite Delta. MATERIAIS E MÉTODOS: A população do estudo consistiu de setenta e sete (77) pacientes com hepatite Delta e cento e trinta e sete (137) doadores de sangue elegíveis que compõem o grupo controle. As regiões genômicas de interesse dos genes IL6, TNFα e IL10 foram amplificadas por PCR-RFLP. A dosagem das citocinas foi realizada por citometria de fluxo. RESULTADOS: Os genótipos G/A (TNFα -308G/A) e G/C (IL6 -174G/C) parecem ser fatores de risco para infecção por HDV. A análise das concentrações de citocinas séricas no grupo HDV mostrou que as citocinas IL-2 (p<0,0001), IL-4 (p<0,0001), IL-6 (p<0,0001), IL-10 (p<0,0031) encontraram significativamente aumentou no grupo HDV. Os níveis séricos de citocinas para indivíduos do grupo HDV IL-6G/C+C/C + IL-10A/G+G/G demonstraram níveis mais elevados de citocinas IL-2 (p<0,0066), IL-4 (p<0,0053) , IL-6 (p<0,0076), IL-10 (p<0,0309) e IFN-γ (p<0,0199). CONCLUSÃO: Nossos achados demonstram relevância na influência dos SNPs estudados em pacientes com HDV no perfil de citocinas. TNFɑ -308G / A e IL6 -174G / C podem predispor indivíduos à infecção por hepatite D. A presença dos genótipos combinados IL-6G / C + CC + IL-10A / G + G / G altera o perfil das citocinas IL-2, IL- 4, IL-6, IL-10 e IFN-γ. No entanto, estudos futuros devem ser realizados para melhor elucidar a influência desses SNPs na patogênese da Hepatite Deltapt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.programPPGH -PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS APLICADAS À HEMATOLOGIApt_BR
dc.relation.references65 promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol505 Genet. 2003;12(19):2541–6.506 56. Basturk B, Karasu Z, Kilic M, Ulukaya S, Boyacioglu S, Oral B. Association of TNF-α507 -308 polymorphism with the outcome of hepatitis B virus infection in Turkey. Infect508 Genet Evol. 2008;8(1):20–5.509 57. Wang B, Wang J, Zheng Y, Zhou S, Zheng J, Wang F, et al. A study of TNF-alpha-238510 and -308 polymorphisms with different outcomes of persistent hepatitis B virus511 infection in China. Pathology. 2010;42(7):674–80.512 58. Ferreira S da C, Chachá SGF, Souza FF, Teixeira AC, de Carvalho Santana R,513 Deghaide NHS, et al. IL-18 , TNF , and IFN-γ alleles and genotypes are associated514 with susceptibility to chronic hepatitis B infection and severity of liver injury. J Med515 Virol [Internet]. 2015 Oct;87(10):1689–96. Available from:516 http://doi.wiley.com/10.1002/jmv.24225517 59. Dai CY, Chuang WL, Lee LP, Chen SC, Hou NJ, Lin ZY, et al. Associations of tumour518 necrosis factor alpha promoter polymorphisms at position -08 and -238 with clinical519 characteristics of chronic hepatitis C. J Viral Hepat. 2006;13(11):770–4.520 60. Liu L, Yang X, Chen X, Kan T, Shen Y, Chen Z, et al. Association between TNF-α521 polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep [Internet].522 2012 Mar 14;39(3):2683–8. Available from: http://link.springer.com/10.1007/s11033-523 011-1022-9524 61. Zhang Y, Cao Y, Xin L, Gao N, Liu B. Association between rs1800629 polymorphism525 in tumor necrosis factor-α gene and dilated cardiomyopathy susceptibility. Medicine526 (Baltimore) [Internet]. 2018 Dec;97(50):e13386. Available from:527 http://journals.lww.com/00005792-201812140-00031528 62. Pawlik A, Domanski L, Rozanski J, Florczak M, Dabrowska-Zamojcin E, Dutkiewicz529 G, et al. IL-2 and TNF-α Promoter Polymorphisms in Patients With Acute Kidney530 Graft Rejection. Transplant Proc [Internet]. 2005 Jun;37(5):2041–3. Available from:531 https://linkinghub.elsevier.com/retrieve/pii/S0041134505003301532 63. Aoki T, Hirota T, Tamari M, Ichikawa K, Takeda K, Arinami T, et al. An association533 between asthma and TNF-308G/A polymorphism: meta-analysis. J Hum Genet534 [Internet]. 2006 Aug 25;51(8):677–85. Available from:535 66 http://www.nature.com/articles/jhg2006103536 64. ZHANG S, WANG C, XI B, LI X. Association between the tumour necrosis factor-537 α−308G/A polymorphism and chronic obstructive pulmonary disease: An update.538 Respirology [Internet]. 2011 Jan;16(1):107–15. Available from:539 http://doi.wiley.com/10.1111/j.1440-1843.2010.01879.x540 65. Khan S, Mandal RK, Jawed A, Dar SA, Wahid M, Panda AK, et al. TNF-α -308 G541 &gt; A (rs1800629) Polymorphism is Associated with Celiac Disease: A Meta-analysis542 of 11 Case-Control Studies. Sci Rep [Internet]. 2016 Dec 6;6(1):32677. Available543 from: http://www.nature.com/articles/srep32677544 66. El-Maadawy EA, Talaat RM, Ahmed MM, El-Shenawy SZ. Interleukin-6 promotor545 gene polymorphisms and susceptibility to chronic hepatitis B virus in Egyptians. Hum546 Immunol [Internet]. 2019;80(3):208–14. Available from:547 https://doi.org/10.1016/j.humimm.2018.12.009548 67. Sutherland GR, Baker E, Callen DF, Hyland VJ, Wong G, Clark S, et al. Interleukin 4549 is at 5q31 and interleukin 6 is at 7p15. Hum Genet. 1988;79(4):335–7.550 68. Fishman D, Faulds G, Jeffey R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The551 effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription552 and plasma IL-6 levels, and an association with systemic- onset juvenile chronic553 arthritis. J Clin Invest. 1998;102(7):1369–76.554 69. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The555 effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription556 and plasma IL-6 levels, and an association with systemic-onset juvenile chronic557 arthritis. J Clin Invest [Internet]. 1998 Oct 1;102(7):1369–76. Available from:558 http://www.jci.org/articles/view/2629559 70. Ahmed IH, Ghali ZH. Transversion and transition mutations of interleukin-6 gene -174560 (G/C) in patients with type-2 diabetes mellitus. Gene Reports [Internet]. 2019561 Dec;17:100478. Available from:562 https://linkinghub.elsevier.com/retrieve/pii/S2452014419301207563 71. González-Castro TB, Hernández-Díaz Y, Pérez-Hernández N, Tovilla-Zárate CA,564 Juárez-Rojop IE, López-Narvaez ML, et al. Interleukin 6 (RS1800795) gene565 polymorphism is associated with cardiovascular diseases: A meta-analysis of 74 studies566 67 with 86,229 subjects. EXCLI J. 2019;18(1):331–55.567 72. Rodrigues KF, Pietrani NT, Bosco AA, Campos FMF, Sandrim VC, Gomes KB. IL-6,568 TNF-α, and IL-10 levels/polymorphisms and their association with type 2 diabetes569 mellitus and obesity in Brazilian individuals. Arch Endocrinol Metab [Internet]. 2017570 Feb 16;61(5):438–46. Available from:571 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-572 39972017000500438&lng=en&tlng=en573 73. Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, et al.574 Polymorphism in cytokine genes as prognostic markers in Hodgkin’s lymphoma. Ann575 Oncol [Internet]. 2007 Aug;18(8):1376–81. Available from:576 https://linkinghub.elsevier.com/retrieve/pii/S0923753419428974577 74. Sławińska M, Zabłotna M, Gleń J, Lakomy J, Nowicki RJ, Sobjanek M. STAT3578 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell579 carcinoma in patients from northern Poland. Arch Dermatol Res [Internet]. 2019 Nov580 24;311(9):697–704. Available from: http://link.springer.com/10.1007/s00403-019-581 01952-7582 75. Pooja S, Chaudhary P, Nayak L V., Rajender S, Saini KS, Deol D, et al. Polymorphic583 variations in IL-1β, IL-6 and IL-10 genes, their circulating serum levels and breast584 cancer risk in Indian women. Cytokine [Internet]. 2012 Oct;60(1):122–8. Available585 from: https://linkinghub.elsevier.com/retrieve/pii/S1043466612004863586 76. Jafari-Nedooshan J, Dastgheib SA, Kargar S, Zare M, Raee-Ezzabadi A, Heiranizadeh587 N, et al. Association of IL-6 −174 G&gt;C Polymorphism with Susceptibility to588 Colorectal Cancer and Gastric Cancer: a Systematic Review and Meta-Analysis. Acta589 Medica (Hradec Kral Czech Republic) [Internet]. 2019;62(4):137–46. Available from:590 https://actamedica.lfhk.cuni.cz/62/4/0137/591 77. Sawkulycz X, Bradburn S, Robinson A, Payton A, Pendleton N, Murgatroyd C.592 Regulation of Interleukin 6 by a polymorphic CpG within the frontal cortex in593 Alzheimer’s disease. Neurobiol Aging [Internet]. 2020 Apr; Available from:594 https://linkinghub.elsevier.com/retrieve/pii/S0197458020301275595 78. Grocott HP, White WD, Morris RW, Podgoreanu M V., Mathew JP, Nielsen DM, et al.596 Genetic Polymorphisms and the Risk of Stroke After Cardiac Surgery. Stroke597 68 [Internet]. 2005 Sep;36(9):1854–8. Available from:598 https://www.ahajournals.org/doi/10.1161/01.STR.0000177482.23478.dc599 79. Müller-Steinhardt M, Härtel C, Müller B, Kirchner H, Fricke L. The interleukin-6 -600 174promoter polymorphism is associated with long-term kidney allograft survival.601 Kidney Int [Internet]. 2002 Nov;62(5):1824–7. Available from:602 https://linkinghub.elsevier.com/retrieve/pii/S0085253815487411603 80. Cussigh A, Falleti E, Fabris C, Bitetto D, Cmet S, Fontanini E, et al. Interleukin 6604 promoter polymorphisms influence the outcome of chronic hepatitis C.605 Immunogenetics [Internet]. 2011 Jan 12;63(1):33–41. Available from:606 http://link.springer.com/10.1007/s00251-010-0491-7607 81. Falleti E, Fabris C, Vandelli C, Colletta C, Cussigh A, Smirne C, et al. Genetic608 polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis609 C. Hum Immunol [Internet]. 2010;71(10):999–1004. Available from:610 http://dx.doi.org/10.1016/j.humimm.2010.06.006611 82. Barrett S, Collins M, Kenny C, Ryan E, Keane CO, Crowe J. Polymorphisms in tumour612 necrosis factor-α, transforming growth factor-β, interleukin-10, interleukin-6,613 interferon-γ, and outcome of hepatitis C virus infection. J Med Virol. 2003;71(2):212–614 8.615 83. Giannitrapani L, Soresi M, Giacalone A, Campagna ME, Marasà M, Cervello M, et al.616 IL-6-174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and617 hepatocellular carcinoma. Omi A J Integr Biol. 2011;15(3):183–6.618 84. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson I V. An619 investigation of polymorphism in the interleukin-10 gene promoter. Eur J620 Immunogenet. 1997;24(1):1–8.621 85. Kim JM, Brannan CI, Copeland NG, Jenkinst NA, Tariq A. Structure of the mouse IL-622 10 gene and chromosomal localization of the mouse and human genes . J M Kim , C I623 Brannan , N G Copeland , N A Jenkins , T A Khan and K W Moore Why The JI ?624 Submit online . • No Triage ! Every submission reviewed by practicing sc. 2019;625 86. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RGJ, Huizinga TWJ.626 Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad627 Sci U S A. 1998;95(16):9465–70 87. Ribeiro CSS, Visentainer JEL, Moliterno RA. Association of cytokine genetic629 polymorphism with hepatites B infection evolution in adult patients. Mem Inst630 Oswaldo Cruz. 2007;102(4):435–40.631 88. Gao QJ, Liu DW, Zhang SY, Jia M, Wang LM, Wu LH, et al. Polymorphisms of some632 cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol.633 2009;15(44):5610–9.634 89. Gao QJ, Zhang S, Wu L, Jia M, Mi Y, Liu D. Association of IL-10-1082 and IL-10-635 592 polymorphisms with chronic hepatitis B and/or hepatitis C virus infection among636 plasma donors in a rural area of Hebei Province, China. Wei Sheng Yan Jiu [Internet].637 2011;40(6):709—713. Available from: http://europepmc.org/abstract/MED/22279662638 90. Srivastava M, Ranjan A, Choudhary JK, Tripathi MK, Verma S, Dixit VK, et al. Role639 of proinflammatory cytokines (Interferon Gamma) and anti-inflammatory cytokine640 (Interleukin-10) gene polymorphisms in chronic hepatitis B Infection: An Indian641 Scenario. J Interf Cytokine Res. 2014;34(7):547–51.642 91. Manolova I, Miteva L, Ivanova M, Kundurzhiev T, Stoilov R, Stanilova S. The643 Synergistic Effect of TNFA and IL10 Promoter Polymorphisms on Genetic644 Predisposition to Systemic Lupus Erythematosus. Genet Test Mol Biomarkers645 [Internet]. 2018 Feb;22(2):135–40. Available from:646 http://www.liebertpub.com/doi/10.1089/gtmb.2017.0169647 92. Bai H, Jing D, Guo A, Yin S. Association between interleukin 10 gene polymorphisms648 and risk of type 2 diabetes mellitus in a Chinese population. J Int Med Res [Internet].649 2014 Jun 23;42(3):702–10. Available from:650 http://journals.sagepub.com/doi/10.1177/0300060513505813651 93. Zhu Z, Liu J-B, Liu X, Qian L. Association of interleukin 10 rs1800896 polymorphism652 with susceptibility to breast cancer: a meta-analysis. J Int Med Res [Internet]. 2020 Apr653 29;48(4):030006052090486. Available from:654 http://journals.sagepub.com/doi/10.1177/0300060520904863655 94. Chomczynski P, Sacchi N. The single-step method of RNA isolation by acid656 guanidinium thiocyanate–phenol–chloroform extraction: twenty-something years on.657 Nat Protoc [Internet]. 2006 Aug 27;1(2):581–5. Available from:658 http://www.nature.com/articles/nprot.2006.83659 70 95. TarragÔ AM, da Costa AG, Pimentel JPD, Gomes STM, Freitas FB, Lalwani P, et al.660 Combined impact of hepatitis C virus genotype 1 and interleukin-6 and tumor necrosis661 factor-α polymorphisms on serum levels of pro-inflammatory cytokines in Brazilian662 HCV-infected patients. Hum Immunol. 2014;75(11):1075–83.663 96. Wai C. A simple noninvasive index can predict both significant fibrosis and cirrhosis in664 patients with chronic hepatitis C. Hepatology [Internet]. 2003 Aug;38(2):518–26.665 Available from: http://doi.wiley.com/10.1053/jhep.2003.50346666 97. Brasil. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite667 C e Coinfecções. Ministério da Saúde - Secretaria de Vigilância em Saúde -668 Departamento de DST, Aids e Hepatites Virais. 2015. 0–88 p.669 98. Couto I, Victoria M, Veloso VG, Rodrigues L, Grinsztejn B, Lacerda M, et al.670 Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-671 ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection. PLoS One.672 2017;12(3):1–15.673 99. da Silva Victoria F, de Oliveira CMC, Victoria MB, Victoria CB, Ferreira LCL.674 Characterization of HBeAg-negative chronic hepatitis B in western Brazilian675 Amazonia. Brazilian J Infect Dis. 2008;12(1):27–37.676 100. Castilho MDC, De Oliveira CMC, De Lima Gimaque JB, Di Tommaso Leão J, Braga677 WSM. Epidemiology and molecular characterization of hepatitis B virus infection in678 isolated villages in the western Brazilian Amazon. Am J Trop Med Hyg.679 2012;87(4):768–74.680 101. Braga WSM, De Oliveira CMC, De Araújo JR, Castilho MDC, Rocha JM, Gimaque681 JBDL, et al. Chronic HDV/HBV co-infection: Predictors of disease stage - A case682 series of HDV-3 patients. J Hepatol [Internet]. 2014;61(6):1205–11. Available from:683 http://dx.doi.org/10.1016/j.jhep.2014.05.041684 102. De Oliveira MS, Do Valle SDCN, Silva RPM, De Figueiredo EN. Hepatite B e a685 superinfecção por vírus D em pacientes crônicos na Amazônia ocidental brasileira. Rev686 Epidemiol e Control Infecção. 2015;5(2):72–8.687 103. Bicer S, Giray T, Çöl D, Erdağ GÇ, Vitrinel A, Gürol Y, et al. Virological and clinical688 characterizations of respiratory infections in hospitalized children. Ital J Pediatr689 [Internet]. 2013;39(1):22. Available from:690 71 http://ijponline.biomedcentral.com/articles/10.1186/1824-7288-39-22691 104. Min C-Y, Song JY, Jeong SJ. Characteristics and prognosis of hepatic cytomegalovirus692 infection in children: 10 years of experience at a university hospital in Korea. Korean J693 Pediatr [Internet]. 2017;60(8):261. Available from:694 http://kjp.or.kr/journal/view.php?doi=10.3345/kjp.2017.60.8.261695 105. Vingerhoets J, Michielsen P, Vanham G, Bosmans E, Paulij W, Ramon A, et al. HBV-696 specific lymphoproliferative and cytokine responses in patients with chronic hepatitis697 B. J Hepatol. 1998;28(1):8–16.698 106. Tejima K, Masuzaki R, Ikeda H, Yoshida H, Tateishi R, Sugioka Y, et al.699 Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B700 with the same grade of liver stiffness and splenomegaly. J Gastroenterol.701 2010;45(8):876–84.702 107. Joo EJ, Chang Y, Yeom JS, Lee YG, Ryu S. Hepatitis B infection is associated with an703 increased incidence of thrombocytopenia in healthy adults without cirrhosis. J Viral704 Hepat. 2017;24(3):253–8.705 108. LIMA DS, MURAD JÚNIOR AJ, BARREIRA MA, FERNANDES GC, COELHO706 GR, GARCIA JHP. Liver Transplantation in Hepatitis Delta: South America707 Experience. Arq Gastroenterol. 2018;55(1):14–7.708 109. Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia:709 Clinical and laboratory characteristics compared with chronic immune710 thrombocytopenic purpura. Br J Haematol. 2005;129(6):818–24.711 110. manesis1994.pdf.712 111. Sanyal AJ, Freedman AM, Purdum PP, Shiffman ML, Luketic VA. The hematologic713 consequences of transjugular intrahepatic portosystemic shunt. Hepatology.714 1996;23(1):32–9.715 112. Dou J, Lou Y, Wu J, Lu Y, Jin Y. Thrombocytopenia in patients with hepatitis B virus-716 related chronic hepatitis: Evaluation of the immature platelet fraction. Platelets.717 2014;25(6):399–404.718 113. Doi T. Mechanisms for increment of platelet associated IgG and platelet surface IgG719 and their implications in immune thrombocytopenia associated with chronic viral liver720 72 disease. Hepatol Res [Internet]. 2002 Sep;24(1):23–33. Available from:721 https://linkinghub.elsevier.com/retrieve/pii/S1386634602000104722 114. Lebensztejn DM, Kaczmarski M. Lamivudine-associated thrombocytopenia. Am J723 Gastroenterol [Internet]. 2002 Oct;97(10):2687–8. Available from:724 http://www.nature.com/doifinder/10.1111/j.1572-0241.2002.06063.x725 115. Frasca D, Blomberg BB. Inflammaging decreases adaptive and innate immune726 responses in mice and humans. Biogerontology [Internet]. 2016 Feb 29;17(1):7–19.727 Available from: http://link.springer.com/10.1007/s10522-015-9578-8728 116. Frasca D, Blomberg BB, Paganelli R. Aging, Obesity, and Inflammatory Age-Related729 Diseases. Front Immunol [Internet]. 2017 Dec 7;8. Available from:730 http://journal.frontiersin.org/article/10.3389/fimmu.2017.01745/full731 117. Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and732 Age-Related Diseases: Role of Inflammation Triggers and Cytokines. Front Immunol733 [Internet]. 2018 Apr 9;9. Available from:734 http://journal.frontiersin.org/article/10.3389/fimmu.2018.00586/full735 118. Rhode PC, Froehlich-Grobe K, Hockemeyer JR, Carlson JA, Lee J. Assessing stress in736 disability: Developing and piloting the Disability Related Stress Scale. Disabil Health J737 [Internet]. 2012 Jul;5(3):168–76. Available from:738 http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L473739 77132740 119. Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: Does741 it differ from hepatitis B monoinfection. Saudi J Gastroenterol. 2012;18(1):18–22.742 120. Takyar V, Surana P, Kleiner DE, Wilkins K, Hoofnagle JH, Liang TJ, et al.743 Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol744 Ther. 2017;45(1):127–38.745 121. Negro F. Hepatitis D virus coinfection and superinfection. Cold Spring Harb Perspect746 Med. 2014;4(11).747 122. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al.748 Prediction of liver histological lesions with biochemical markers in patients with749 chronic hepatitis B. J Hepatol. 2003;39(2):222–30.750 73 123. Saxena R, Kaur J. Th1/Th2 cytokines and their genotypes as predictors of hepatitis B751 virus related hepatocellular carcinoma. World J Hepatol. 2015;7(11):1572–80.752 124. Conde SR et al. Association of cytokine gene polymorphisms and serum concentrations753 with the outcome of chronic hepatitis B. Cytokine [Internet]. 2013;61(3):940–4.754 Available from: http://dx.doi.org/10.1016/j.cyto.2013.01.004755 125. Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the756 transcriptional regulation of the TNF gene: Relevance to disease. J Leukoc Biol.757 1999;66(4):562–6.758 126. Jeng JE, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, et al. Tumor necrosis759 factor-α 308.2 polymorphism is associated with advanced hepatic fibrosis and higher760 risk for hepatocellular carcinoma. Neoplasia. 2007;9(11):987–92.761 127. Radwan MI, Pasha HF, Mohamed RH, Hussien HIM, El-Khshab MN. Influence of762 transforming growth factor-β1 and tumor necrosis factor-α genes polymorphisms on763 the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C764 patients. Cytokine [Internet]. 2012;60(1):271–6. Available from:765 http://dx.doi.org/10.1016/j.cyto.2012.05.010766 128. Li C, Zhi-Xin C, Li-Juan Z, Chen P, Xiao-Zhong W. The association between cytokine767 gene polymorphisms and the outcomes of chronic HBV infection. Hepatol Res.768 2006;36(3):158–66.769 129. Giannitrapani L, Soresi M, Balasus D, Licata A, Montalto G. Genetic association of770 interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular771 carcinoma. World J Gastroenterol. 2013;19(16):2449–55.772 130. Xia C, Liu Y, Chen Z, Zheng M. Involvement of Interleukin 6 in Hepatitis B Viral773 Infection. Cell Physiol Biochem. 2015;37(2):677–86.774 131. Corchado S, Márquez M, Montes de Oca M, Romero-Cores P, Fernández-Gutiérrez C,775 Girón-González JA. Influence of Genetic Polymorphisms of Tumor Necrosis Factor776 Alpha and Interleukin 10 Genes on the Risk of Liver Cirrhosis in HIV-HCV777 Coinfected Patients. PLoS One. 2013;8(6):1–8.778 132. Ramos JA, Silva R, Hoffmann L, Ramos ALA, Cabello PH, Ürményi TP, et al.779 Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous780 74 clearance of hepatitis C virus in a population from Rio de Janeiro. BMC Res Notes.781 2012;5:0–5.782 133. Grünhage F, Nattermann J. Viral hepatitis: Human genes that limit infection. Best Pract783 Res Clin Gastroenterol [Internet]. 2010;24(5):709–23. Available from:784 http://dx.doi.org/10.1016/j.bpg.2010.07.009785 134. Gigi E, Raptopoulou-Gigi M, Kalogeridis A, Masiou S, Orphanou E, Vrettou E, et al.786 Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in787 patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-788 limited disease. J Viral Hepat. 2008;15(2):145–54.789 135. Cacciarelli T V., Martinez OM, Gish RG, Villanueva JC, Krams SM.790 Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and791 posttreatment with interferon alfa. Hepatology. 1996;24(1):6–9.792 136. Li X, Liu X, Tian L, Chen Y. Cytokine-Mediated Immunopathogenesis of Hepatitis B793 Virus Infections. Clin Rev Allergy Immunol. 2016;50(1):41–54.794 137. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and Functions795 of the IL-10 Family of Cytokines in Inflammation and Disease. Annu Rev Immunol796 [Internet]. 2011 Apr 23;29(1):71–109. Available from:797 http://www.annualreviews.org/doi/10.1146/annurev-immunol-031210-101312798 138. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-799 20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol [Internet]. 2008800 May;121(5):1108–11. Available from:801 https://linkinghub.elsevier.com/retrieve/pii/S0091674908004107802 139. Fan X, Liu W, Li C. [Determination of serum cytokines in individuals with HCV803 infection]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi [Internet]. 2000804 Jun;14(2):145–7. Available from: https://europepmc.org/article/med/11503046805 140. Spanakis NE, Garinis GA, Alexopoulos EC, Patrinos GP, Menounos PG, Sklavounou806 A, et al. Cytokine serum levels in patients with chronic HCV infection. J Clin Lab807 Anal. 2002;16(1):40–6.808 141. Zhang, L., Miao, L., Han, F., & Dou XG. Cytokine levels in serum of patients with809 chronic hepatitis C and its significance. Chinese J Cell Mol Immunol [Internet].810 75 2011;27(3):301–3. Available from: https://europepmc.org/article/med/21419051811 142. Cheng LS, Liu Y, Jiang W. Restoring homeostasis of CD4+ T cells in hepatitis-B-812 virusrelated liver fibrosis. World J Gastroenterol. 2015;21(38):10721–31.813 143. Hao C, Wang J, Kang W, Xie Y, Zhou Y, Ma L, et al. Kinetics of Th17 cytokines814 during telbivudine therapy in patients with chronic hepatitis b. Viral Immunol.815 2013;26(5):336–42.816 144. Zheng Y, Huang Z, Chen X, Tian Y, Tang J, Zhang Y, et al. Effects of telbivudine817 treatment on the circulating CD4+ T-cell subpopulations in chronic hepatitis B patients.818 Mediators Inflamm. 2012;2012.819 145. De Souza-Cruz S, Victória MB, Tarragô AM, Da Costa AG, Pimentel JPD, Pires EF, et820 al. Liver and blood cytokine microenvironment in HCV patients is associated to liver821 fibrosis score: A proinflammatory cytokine ensemble orchestrated by TNF and tuned822 by IL-10 Microbe-host interactions and microbial pathogenicity. BMC Microbiol823 [Internet]. 2016;16(1):1–12. Available from: http://dx.doi.org/10.1186/s12866-015-824 0610-6825 146. Othman MS, Aref AM, Mohamed AA, Ibrahim WA. Serum Levels of Interleukin-6826 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients.827 ISRN Hepatol [Internet]. 2013;2013:1–9. Available from:828 https://www.hindawi.com/archive/2013/412317/829 147. Sghaier I, Mouelhi L, Rabia NA, Alsaleh BR, Ghazoueni E, Almawi WY, et al.830 Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma831 in HCV infected patients. Cytokine [Internet]. 2017 Jan;89:62–7. Available from:832 https://linkinghub.elsevier.com/retrieve/pii/S1043466616305440833 148. Crispim MAE, Fraiji NA, Campello SC, Schriefer NA, Stefani MMA, Kiesslich D.834 Molecular epidemiology of hepatitis B and hepatitis delta viruses circulating in the835 Western Amazon region, North Brazil. BMC Infect Dis. 2014;14(1):1–9pt_BR
dc.publisher.initialsUEApt_BR
Aparece nas coleções:DISSERTAÇÃO - PPCAH Programa de Pós-Graduação em Ciências Aplicadas à Hematologia

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Estudo de caracterização dos polimorfismos das regiões promotoras das citocinas fator de necrose tumoral a (TNF-a), interleucina 6(IL-6) e interleucina 10(IL-10) em pacientes com hepatite Delta.pdf3,27 MBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.